SCHEMBL15316684

SCHEMBL15316684

Cc1ccc(O)c(/C=C/c2ccccc2Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
RAB9A P51151 4/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 3/20 0.44
RELA Q04206 2/20 0.44
HPGD P15428 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
CHAT P28329 1/20 0.44
HTT P42858 1/20 0.44
ABCG2 Q9UNQ0 3/20 0.43
HSP90AA1 P07900 2/20 0.43
AGTR1 P30556 1/20 0.43
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP1B1 Q16678 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901263 0.82 ERN1 (0.53) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL901262 0.82 ERN1 (0.53) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL3668133 0.82 ALOX5 (0.50) MEN1KMT2ARAB9AKDM4ELMNA
SCHEMBL27876530 0.79 TRPA1 (0.60) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL28472052 0.76 ALOX5 (0.54) MEN1KMT2ARAB9AKDM4ELMNA
SCHEMBL28472054 0.76 ALOX5 (0.54) MEN1KMT2ARAB9AKDM4ELMNA
SCHEMBL31619510 0.75 NFE2L2 (0.42) MEN1KMT2ARAB9ALMNAMAPT
SCHEMBL34474338 0.74 MEN1 (0.61) MEN1KMT2ARAB9AKDM4ELMNA
SCHEMBL22624703 0.74 MEN1 (0.61) MEN1KMT2ARAB9AKDM4ELMNA
SCHEMBL23332267 0.74 NFE2L2 (0.66) MEN1KMT2AKDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130274466-A1 PROCESS FOR THE PREPARATION OF TETRACYCLIC DERIVATIVES AND INTERMEDIATE PRODUCTS USED IN THE PROCESS ALPHORA RESEARCH INC. (CA) 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274466-A1 PROCESS FOR THE PREPARATION OF TETRACYCLIC DERIVATIVES AND INTERMEDIATE PRODUCTS USED IN THE PROCESS NISCH, SSRP1, UMPS MEN1 1163/4885KMT2A 3613/4885RAB9A 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.